Abstract 2203P
Background
Malignant pleural mesothelioma (MPM) is a rare and aggressive disease with poor prognosis. MPM is classified into three histological subtypes: epithelioid, biphasic, and sarcomatoid. This classification does not account for survival differences and intratumor heterogenity, especially for epithelioid MPM (eMPM) that is the most common subtype. The aim of this study is to evaluate transcriptomic differences of eMPM based on prognostic classes.
Methods
MPM patients with available FFPE tissue were retrospectively and prospectively enrolled at Fondazione IRCCS Istituto Nazionale dei Tumori of Milan and Azianda Sanitaria Universitaria Giuliano Isontina of Trieste between 2006 and 2021 within the granted Italian MOH project, GR-2016-02361229. RNA was automatically extracted and quantified using a fluorometer. Transcriptome was assessed through the 3’DGE method. Patients were divided into three groups based on months (mo) of survival: long survivors (LS) > 36 mo, normal survivors (NS) > 12 and ≤ 36 m, and short survivors (SS) ≤ 12 mo. Evaluation of differential gene expression (GED) between SS and LS was performed for single genes. Moreover, in the same setting, a gene set enrichment analysis (GSEA) was also performed.
Results
125 eMPM cases were enrolled, 90 (72%) males and 35 (28%) females, with a median age at diagnosis of 72 years. At a median follow-up of 88 mo, the median overall survival (OS) was 21 mo. Among patients, 33 were LS, 54 were NS, and 38 were SS. GED showed higher levels of NUF2 and TUBB3, genes involved in the epithelial-mesenchimal-transition (EMT), and a lower expression of ADH1B, PLA2G2A, genes related to metabolism, in SS. EMT, metabolism signature and cell proliferation were confirmed by GSEA analysis as more positively correlated pathways while inflammation and immune response related pathways were negatively correlated in SS.
Conclusions
Transcriptomic characterization of eMPM reinforces the hypothesis that cell cycle, EMT and immune components could have an impact on eMPM outcome and could be exploited as therapeutic strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Italian Ministry of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2161P - Organization of hospital pharmaceutical consultations for cancer patients receiving oral anticancer drugs: A nationwide cross-sectional study
Presenter: Florian Slimano
Session: Poster session 07
2162P - Can artificial intelligence provide accurate and reliable answers to cancer patients' questions? Comparison of chatbots based on the ESMO Patient Guide about cancer pain
Presenter: Kadriye Bir Yucel
Session: Poster session 07
2163P - Supportive care in French community pharmacies: OncoPharma certification
Presenter: Jérôme Sicard
Session: Poster session 07
2164P - The impact of cancer patients’ face masks on oxygenation and Co2 retention during treatment
Presenter: Mert Sahin
Session: Poster session 07
2165P - A French overview of electronic patient-reported outcomes use in 2022
Presenter: Melina Hocine
Session: Poster session 07
2166P - Long-term consequences of SARS-CoV-2 infection in cancer patients
Presenter: Yana Debie
Session: Poster session 07
2167P - Are bone targeted agents (BTAs) still useful in times of immunotherapy? The SAKK 80/19 BTA study
Presenter: Michael Mark
Session: Poster session 07
2168P - At-home infusion of immunotherapy for patients with solid tumors: First results from a single-centre program
Presenter: Javier Marco Hernández
Session: Poster session 07
2169P - Immunotherapy-based treatment in elderly cancer patients: A real-world multicenter study
Presenter: Mengye He
Session: Poster session 07
2171P - Incidence of adverse events in patients treated with a combination of immune checkpoint blockers and chemotherapy: A real life cohort
Presenter: Layal Rached
Session: Poster session 07